INmune Bio Inc. Joins Baird 2024 Global Healthcare Conference
INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference
Boca Raton, Florida — INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology firm dedicated to harnessing the innate immune system in the fight against disease, has announced its participation in notable investor conferences this September and October.
Details on the Baird Conference
The Baird 2024 Global Healthcare Conference is scheduled for September 10-11, 2024, where INmune Bio's management will take part. They are set to present on Tuesday, September 10, from 8:30 to 9:00 AM Eastern Time. The presentation will take place in Session III at Empire Ballroom B, located on the Mezzanine Level.
About INmune Bio Inc.
INmune Bio, Inc. focuses on advanced therapeutics that aim to strategically activate the innate immune system to combat diseases. With a robust pipeline, the company has two pivotal product platforms currently in clinical trials. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform, which employs innovative technology to neutralize soluble TNF—a significant factor in immune system dysfunction—features XPRO, the first DN-TNF product, undergoing trials to assess its effectiveness in treating Mild Alzheimer’s disease. Future therapeutic applications include treatments for resistant depression and oncology in due course.
Natural Killer Cell Priming Platform
Alongside the DN-TNF platform, INmune Bio is advancing the Natural Killer Cell Priming Platform, which includes INKmune™. This therapy is designed to activate a patient's natural killer (NK) cells to target cancerous cells effectively. Currently, INKmune™ is involved in a Phase I/II clinical trial for men diagnosed with metastatic castrate-resistant prostate cancer.
Contact Information
For more information, INmune Bio has made it easy to connect. David Moss, CFO, can be reached at (858) 964-3720 or via email at info@inmunebio.com. For investor inquiries, Mike Moyer, Managing Director at LifeSci Advisors, is available to assist at mmoyer@lifesciadvisors.com.
Frequently Asked Questions
What is the primary focus of INmune Bio Inc.?
INmune Bio Inc. specializes in developing treatments that leverage the innate immune system to fight various diseases, including cancer and neurodegenerative conditions.
When will INmune Bio present at the Baird 2024 Global Healthcare Conference?
INmune Bio's presentation is scheduled for September 10, 2024, from 8:30 to 9:00 AM Eastern Time.
What products are currently in clinical trials under INmune Bio?
INmune Bio has two primary platforms in clinical trials: the DN-TNF product platform with XPRO for Mild Alzheimer’s and the Natural Killer Cell Priming Platform featuring INKmune™ for cancer treatment.
How does INmune Bio's XPRO work?
XPRO utilizes dominant-negative technology to selectively neutralize soluble TNF, aiming to improve outcomes for patients with Mild Alzheimer’s disease.
Where can I find more information about INmune Bio's products?
You can learn more about INmune Bio and its innovations by visiting their official website at www.inmunebio.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Equature's 2024.3 Software Revolutionizes Public Safety Operations
- Leinco Technologies Inc. Expands Portfolio with QED Biosciences
- Jamie Foxx Brings Humor to BetMGM's 2024 Football Campaign
- Wipfli Unveils 2024 Annual Report Detailing Growth and Innovation
- Costco to Expand with Four New Locations by End of 2024
- Bloomberg CityLab 2024: Global Mayors Gather in Mexico City
- Aker ASA Finalizes Aker BioMarine Feed Ingredients Deal
- Papaya Global Reinvents Payroll with Innovative Tech-First Solution
- Real Estate Investment Trusts Drive Global Markets Upward
- Blue Federal Credit Union Achieves Prestigious Awards in 2024
- Healthcare Digital Twins Market to Surge 25.70% Growth Rate
- Trinity Biotech Welcomes Adrian Donohue as CCO
- Global NGS Sample Preparation Market Poised for Growth
- Cambridge Launches Family Business Leadership Programme in 2024
- Allpowers Showcases Innovative Power Solutions at IFA 2024
- Global Four-Wheeler Tires Market Set to Reach $365.5 Billion
- Growth Projections in Global Industrial Distribution Market
- TEN, Ltd. Schedules Q2 2024 Results Event and Conference Call
- Music Licensing, Inc. Expands Portfolio with New Acquisition
- Global PET-CT Scanner Market Set for $4.9 Billion Growth
- EzFill Holdings, Inc. Achieves NASDAQ Listing Compliance Again
- Simtra BioPharma Solutions Welcomes Dr. Mike Schaefers
- DemandScience Achieves a Historic 11th Inc. 5000 Honor
- Altamira Therapeutics Attends H.C. Wainwright Conference 2024
- Healthcare Mobility Solutions Market Foresees Major Growth
Recent Articles
- BoomerangFX Expands Innovative Solutions in Asia and Latin America
- Cork Packaging Market Expected to Hit USD 2.7 Billion Growth
- Fuel for a Cause: Peninsula Bridge Partners with Shell and Loop
- Ukrenergo Board Members Resign Over Politically Motivated Dismissal
- ISA Launches New Enterprise-Control System Integration Certificate
- Simtra BioPharma Solutions Welcomes Dr. Mike Schaefers
- INmune Bio Inc. Joins Baird 2024 Global Healthcare Conference
- Fortun Advance Reports Rapid Asset Growth and Appoints New VP
- Exploring the Expanding DNA and Gene Cloning Market Trends
- Exploring Broadcom's Stock Movements and Price Levels Ahead
- AITX’s RAD Achieves Record Growth and Revenue in Q2 FY 2025
- Understanding Distributions from Allspring Utilities Fund (ERH)
- Rob Faw Unveils Leadership Strategies for Today's Challenges
- Nvidia's Stellar Growth: Should You Buy Shares Now?
- Cathay Pacific Inspects Fleet: 15 A350s Require Repairs
- Maris-Tech Secures Patent for Enhanced Error Correction Method
- Ocugen's Participation in H.C. Wainwright Conference Insight
- OTC Markets Integrates EDGAR Online Data into Nasdaq Platform
- Scorpio Tankers Executes Vessel Sales and Charter Agreements
- TransUnion CEO to Speak at Barclays Global Financial Conference
- Embecta Secures FDA Clearance for Diabetes Patch Pump
- Nathan Gnanasambandam Joins RhythmX AI as VP of AI
- U.S. Steel Shares Drop Amid Concerns Over Ownership Shift
- Class Action Alert: MongoDB Investors Urged to Act Before Deadline
- Tesla's Humanoid Robots: A Game-Changer for the Future?